Because of hepatobiliary diseases’ influence on AST and ALT level, we performed sensitivity analysis to show the distribution of AST/ALT ratio in patients with fatty liver was attenuated to null after excluding patients with cholecystitis, gallstone, and liver cirrhosis (Table S1). This evidence concerns the gene GPT and Cholecystitis.